ClinicalTrials.gg
CompletedNCT04985916Updated Dec 9, 2024

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

A Phase 2 interventional study of Vehicle and botulinum toxin, Type A in Lateral Canthal Lines, LCL and Crow's Feet, sponsored by Eirion Therapeutics Inc.. Completed at 19 sites in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Eirion Therapeutics Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Study summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Read the detailed description

This product is being tested for its ability to reduce lateral canthal lines (LCL), also known as Crow's Feet.

02

Conditions studied

  • Lateral Canthal Lines, LCL
  • Crow's Feet
03

In context

Lead sponsor

Eirion Therapeutics Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to understand and give written
  • 25 - 65 years of age
  • willing to have facial pictures/videos taken per protocol
  • mild or less Crow's Feet wrinkles (IGA 0-2) "at rest"
  • moderate to severe Crow's Feet (IGA 3-4) "on contraction"
  • ability to correctly grade a series of Crow's Feet pictures
  • moderate to severe Crow's Feet (SSA 3-4) "on contraction"
  • have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses are OK)
  • willingness to refrain from the use of facial fillers, retinoids, botulinum toxins, laser treatments, or any product affecting skin remodeling or that might cause an active dermal response during the course of the study
  • female subjects of must have a negative urine pregnancy test and be non-lactating at the Baseline visit
  • female subjects of childbearing potential must utilize one of the following methods of throughout the study: intra-uterine device (IUD), diaphragm, a condom, a spermicidal gel or foam, oral contraceptives (provided subject has been utilizing this method for at least 3 months prior to Baseline and has not changed the brand within this period), or patch, injectable, implantable, or vaginal ring contraceptives. Subjects may also participate if they are surgically sterilized (tubal sterilization or hysterectomy) or are in menopause.
  • subjects should be in good general health as determined by the Investigator and free of any disease that may interfere with study evaluations or the Product.

Exclusion criteria

Exclusion Criteria:

  • history of adverse reactions to any prior botulinum toxin treatments
  • history of vaccination with botulinum toxin
  • history of non-response to any prior botulinum toxin treatments
  • any botulinum toxin treatment anywhere in the prior 6 months
  • history of participation in ET-01-LCL-210 in previous Cohorts 1 or 2 at any time in the past
  • history of periocular surgery, brow lift or related procedures
  • soft tissue augmentation or any procedures affecting the lateral canthal region in the prior 12 months
  • dermabrasion or laser treatment in the periocular region in the last 6 months
  • topical prescription-strength retinoids in the prior 3 months to the treatment area
  • application of any topical prescription medication to the treatment area within 14 days prior to treatment
  • subjects on , concomitant drug therapy (See Section 5.3 below).).
  • present or history of neuromuscular disease, eyelid ptosis, muscle weakness or paralysis
  • present or history of "dry eye"
  • hemophilia, hemorrhagic disorder, hemostatic dysfunction or other blood clotting disorders
  • use of systemic aminoglycosides in the week prior to treatment application
  • participation in another drug trial or receiving any investigational treatment(s) within 30 days of Baseline
  • alcohol or drug abuse within the past 3 years
  • psychiatric disease interfering with the subject's ability to give
  • refusal or inability to comply with the requirements of the protocol for any reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Placebo comparator
    Vehicle

    Vehicle, topical liniment, administered once at baseline

    Biological: Vehicle

  • Experimental
    ET-01, Dose 1

    Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length

    Biological: botulinum toxin, Type A

  • Experimental
    ET-01, Dose 2

    Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline. 250µm microneedle length

    Biological: botulinum toxin, Type A

Interventions

  • BiologicalVehicle

    topical liniment without investigational product

    Also known as: ET-01 Vehicle

  • ET-01 topical liniment

    Also known as: ET-01

06

What researchers measure

Primary outcomes

  1. IGA (Investigators Global Assessment)

    Investigators Global Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).

    Time frame: Week 4

Secondary outcomes

  1. IGA (Investigators Global Assessment)

    Investigators Global Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).

    Time frame: Week 2, 4, 8,12, and 18

  2. SSA (Subject Self-Assessment)

    Subject Self-Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).

    Time frame: Week 2, 4, 8,12, and 18

07

Study locations

19 sites
  • Eirion Research Site
    Scottsdale, Arizona 85255, United States
  • Eirion Research Site
    San Diego, California 92121, United States
  • Eirion Research Site
    Aventura, Florida 33180, United States
  • Eirion Research Site
    Boca Raton, Florida 33486, United States
  • Eirion Research Site
    Miami, Florida 33137, United States
  • Eirion Research Site
    West Palm Beach, Florida 33401, United States
  • Eirion Research Site
    Chicago, Illinois 60654, United States
  • Eirion Research Site
    Louisville, Kentucky 40241, United States
  • Eirion Research Site
    New Orleans, Louisiana 70124, United States
  • Eirion Research Site
    Glenn Dale, Maryland 20769, United States
  • Eirion Research Site
    Clinton Township, Michigan 48038, United States
  • Eirion Research Site
    New Brighton, Minnesota 55112, United States
  • Eirion Research Site
    New York, New York 10075, United States
  • Eirion Research Site
    Exton, Pennsylvania 19341, United States
  • Eirion Research Site
    Newtown Square, Pennsylvania 19073, United States
  • Eirion Research Site
    Greenville, South Carolina 29615, United States
  • Eirion Research Site
    Houston, Texas 77056, United States
  • Eirion Research Site
    Plano, Texas 75093, United States
  • Eirion Research Site
    Norfolk, Virginia 23502, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Feb 2024, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2021
First posted
Aug 2, 2021
StartActual
Jul 19, 2021
Primary completionActual
Feb 8, 2024
CompletionActual
Feb 8, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04985916
Lead sponsor
Eirion Therapeutics Inc.
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Jul 19, 2021
Primary completion
Feb 8, 2024
Completion
Feb 8, 2024
Last update
Dec 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion